RASAL1 and cancer: Interestingly, the present study demonstrated triple concurrence of RASAL1, PTEN, and TP53 alterations, which was associated with the poorest clinical outcomes of cancer and represented a particularly robust biomarker of BRCA being the aggressive triple‐negative basal‐like type.